| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/15/2006 | CN1735402A Polymer composition including large ring alkatriene compound |
| 02/15/2006 | CN1735401A Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same |
| 02/15/2006 | CN1735400A Drug delivery system using subconjunctival depot |
| 02/15/2006 | CN1735355A A process for the preparation of antioxidant preservative from Indian curry leaves |
| 02/15/2006 | CN1735344A Novel substituted benzimidazole dosage forms and method of using same |
| 02/15/2006 | CN1733932A Adenocarcinoma marker and its uses |
| 02/15/2006 | CN1733314A Process for preparing cerebrose albumin magnetic adriamycin nanometer particle |
| 02/15/2006 | CN1733313A Process for preparing poly n-butyl cyan acrylate nanometer particle |
| 02/15/2006 | CN1733312A Fluorouracil-dextran and process for preparing the same |
| 02/15/2006 | CN1733311A Process for preparing nanometer fiber for packaging medicine or growth factor |
| 02/15/2006 | CN1733310A Nanometer particle and medicine capsule of polymeric compound and preparation |
| 02/15/2006 | CN1733309A Process for preparing driving target-directional carrier of folic acid compound mediated |
| 02/15/2006 | CN1733296A Stable liquid interferon formulations |
| 02/15/2006 | CN1732962A Process for preparing nanometer particle of adriacin-PACA-PBCA |
| 02/15/2006 | CN1732954A Freeze dry emulsion of prostaglandin for injection and method for preparing the same |
| 02/15/2006 | CN1732907A Drug releasing membrane controlled by program and its preparation method |
| 02/15/2006 | CN1732900A Implantation body with biological activity of drug controlled-releasing function, its controlled releasing method and preparing method |
| 02/15/2006 | CN1241991C Gelatine compositions |
| 02/15/2006 | CN1241945C Hybrid protein for inhibiting the deatanulation of mastocytes and the use thereof |
| 02/15/2006 | CN1241645C Ingestible compositions containing odoriferous oil |
| 02/15/2006 | CN1241552C Konjaku gluocomannan-calcium alginate microball for carrying medicine and preparing method |
| 02/15/2006 | CN1241551C Medicine-carrying particulates composed of hydrophilic resin and hydrophobic resin and its preparation method |
| 02/15/2006 | CN1241549C Amphoteric liposomes and the use thereof |
| 02/15/2006 | CN1241548C Stable protein: phospholipid composition and method |
| 02/15/2006 | CN1241547C Emulsifying method for preparing emulsion and associated suspension and particles |
| 02/15/2006 | CN1241545C Pharmaceutical composition |
| 02/15/2006 | CN1241542C 乳化组合物 Emulsified composition |
| 02/15/2006 | CN1241532C Complex room container preparation and method for manufacturing the same |
| 02/14/2006 | US6998479 containing an aminooxy (H2NO ) group covalently connected to a glucopyranose unit of cyclodextrin; applicable as complexants, solubilizers, carbonyl reagents, catalysts, or starting materials for the synthesis of various products |
| 02/14/2006 | US6998268 Gene preparations |
| 02/14/2006 | US6998144 2,4-dihydroxybenzoic acid and sucralose in a weight ratio of .01-100% |
| 02/14/2006 | US6998141 Medication combination for hepatoma and pancreatic cancer and preparation protocol |
| 02/14/2006 | US6998140 Use as coating agent and binder for pharmaceutical forms, comprising a methacrylate copolymer of given glass transition temperature range, and a nonionic emulsifier of given hydrophilic-lipophilic balance (HLB); dosage forms |
| 02/14/2006 | US6998138 Benzoic or cinnamoyl ester penetration enhancing agent |
| 02/14/2006 | US6998137 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| 02/14/2006 | US6998136 Stability for injection solutions |
| 02/14/2006 | US6998121 Treatment of Dupuytren's contracture, scleroderma, Peyronie's disease, bovine mastistis and claudication due to peripheral arterial disease |
| 02/14/2006 | US6998115 Biodegradable and biocompatible and may be used in a variety of drug delivery systems; suited for the delivery of polynucleotides |
| 02/14/2006 | US6998105 Low density radionuclide-containing particulate material |
| 02/14/2006 | US6997909 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/14/2006 | US6997863 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 02/14/2006 | CA2378533C Erythropoietin conjugates with polyethylenglycol |
| 02/14/2006 | CA2338684C Injectable propofol formulations |
| 02/14/2006 | CA2292586C Solid pharmaceutical dosage forms in form of a particulate dispersion |
| 02/14/2006 | CA2288793C Poly(vinyl alcohol) cryogel |
| 02/14/2006 | CA2269072C Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/14/2006 | CA2190148C Oral liquid alendronate formulations |
| 02/09/2006 | WO2006015318A2 Antibody conjugated to a drug moiety via a poptidic linker |
| 02/09/2006 | WO2006015261A2 Nucleoside phosphonate conjugates as anti hiv agents |
| 02/09/2006 | WO2006014788A1 Methods of use of herbal compositions |
| 02/09/2006 | WO2006014194A1 Oligosaccharide-containing compositions and uses thereof |
| 02/09/2006 | WO2006013963A1 External preparation for nail |
| 02/09/2006 | WO2006013914A1 Preparation for administration to mouth mucosa |
| 02/09/2006 | WO2006013444A1 Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation |
| 02/09/2006 | WO2006013335A1 Stabilised prostaglandin composition |
| 02/09/2006 | WO2006013039A2 A process for the preparation of a piroxicam: betacyclodextrin inclusion compound |
| 02/09/2006 | WO2005110046A3 Method of enhancing uptake of keratinocyte growth factor |
| 02/09/2006 | WO2005093425A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 58 (gpr58) |
| 02/09/2006 | WO2005093423A3 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) |
| 02/09/2006 | WO2005042027A3 Antagonists of the bradykinin b1 receptor |
| 02/09/2006 | WO2004104490A9 Self-contained heating unit and drug-supply unit employing same |
| 02/09/2006 | WO2003105761A3 Immunotoxin as a therapeutic agent and uses thereof |
| 02/09/2006 | WO2003040693A3 Peptides that home to tumor lymphatic vasculature and methods of using same |
| 02/09/2006 | WO2002011784A3 Pharmaceutical carriers and compositions for transdermal drug delivery |
| 02/09/2006 | US20060030699 Reaction product of thioctic acid and tris(aminoanilinocarbonylalkyl)methylaminocarbonylalkylamine or N,N-bis{N,N-bis(aminobenzoylaminoalkyl)aminocarbonylalkyl}aminoalkanoamide; reaction product with an oligosaccharide; immobilized on support to form sensor chip used for surface plasmon resonance |
| 02/09/2006 | US20060030627 Bioabsorbable granular porous bone filling material and production method thereof |
| 02/09/2006 | US20060030622 Compounds and methods for the treatment of urogenital disorders |
| 02/09/2006 | US20060030540 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 02/09/2006 | US20060029986 Prevention and treatment of cardiovascular pathologies |
| 02/09/2006 | US20060029687 comprises a carrier essentially formed of water, ethoxydiglycol and propylene glycol; anti-oxidant; high stirring speed provides for micronizaton of the components, which is responsible for the stability of the solutions |
| 02/09/2006 | US20060029682 Treatment of wounds and compositions employed |
| 02/09/2006 | US20060029677 Azithromycin dosage forms with reduced side effects |
| 02/09/2006 | US20060029670 Pharmaceutical Formulations and Method for Making |
| 02/09/2006 | US20060029669 Controlled release nateglimide formulation; reducing blood glucose concentration |
| 02/09/2006 | US20060029667 Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
| 02/09/2006 | US20060029660 Non-gelatin capsule shell formulation |
| 02/09/2006 | US20060029656 Replacement enzyme cochleates |
| 02/09/2006 | US20060029655 Method for preparation of vesicles loaded with biological material and different uses thereof |
| 02/09/2006 | US20060029643 glycosylated ceramide and a diacylglycerol in which the constituent fatty acid has an acyl group containing 8 to 18 carbon atoms; enhancing the barrier function of skin and increasing water holding capacity of the skin |
| 02/09/2006 | US20060029642 Methods and compositions for improved chromium complexes |
| 02/09/2006 | US20060029641 Calcium and magnesium nutritional supplement |
| 02/09/2006 | US20060029635 Growth hormone formulations |
| 02/09/2006 | US20060029623 Invert emulsions comprising at least one active agent sensitive to water and cosmetic/dermatological applications thereof |
| 02/09/2006 | US20060029611 Prevention and treatment of amyloidogenic disease |
| 02/09/2006 | US20060029599 Lyophilizing an aqueous formulation comprising a high concentration, 50 mg/ml or more of an immunoglobulin IgG antibody, in particular, daclizumab, in 5-25 mM histidine buffer, having pH 5.5-6.5, 0.005%-0.03% polysorbate, and sucrose |
| 02/09/2006 | US20060029586 Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 02/09/2006 | US20060029569 Water-in-oil emulsions with anionic groups, compositions, and methods |
| 02/09/2006 | US20060029545 Metal radionuclide complexed directly to a an annexin that has been modified to add a sulfhydryl group which participates in the complexation of the metal radionuclide; useful for imaging vascular thrombi |
| 02/09/2006 | CA2638747A1 Combination drug therapy for reducing scar tissue formation |
| 02/09/2006 | CA2618720A1 Clathrate of chlorine dioxide |
| 02/09/2006 | CA2575933A1 Stabilised prostaglandin composition |
| 02/09/2006 | CA2575587A1 Carrier for enteral administration |
| 02/09/2006 | CA2575520A1 Prodrugs activated by rna-dependent dna-polymerases |
| 02/09/2006 | CA2575330A1 Compositions and methods for nutrition supplementation |
| 02/09/2006 | CA2574583A1 Methods of use of herbal compositions |
| 02/09/2006 | CA2574555A1 Phenytoin formulations, and uses thereof in wound healing |
| 02/09/2006 | CA2573000A1 Composition containing statins and omega-3 fatty acids |
| 02/09/2006 | CA2571621A1 Gilsonite derived pharmaceutical delivery compositions and methods : cosmetic and nail applications |
| 02/08/2006 | EP1623994A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/08/2006 | EP1623722A1 Composition for ophthalmic use |